Livtencity (Maribavir) Patent Expiration, LOE Window & CMS Spending

Livtencity (Maribavir) by Takeda: FDA Orange Book core substance LOE 2043-10-11, 0 AB generics, $62.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN215596 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2043-10-11
Last Listed Patent or Exclusivity Date2043-10-11
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$62.1M
2024 Medicare Part D Spend$52.0M
2024 Medicaid Spend$10.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.